Friday, 21 January 2011

A no for oral cladribine in Europe

The European Medicines Agency confirmed its previous negative opinion and adopted a final negative opinion, recommending that oral cladribine, from Serono Europe Ltd, should not be granted a marketing authorisation. Oral cladribine was intended as disease-modifying therapy in relapsing remitting multiple sclerosis.

Click here for EMA statement

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.